Purple Biotech Cash Flow Conversion Efficiency
Purple Biotech cash flow conversion efficiency. Based on the latest financial reports, Purple Biotech (PPBT) has a cash flow conversion efficiency ratio of -0.205x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.50 Million) by net assets ($12.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Purple Biotech (2013–2025)
Cash flow conversion efficiency of Purple Biotech from 2013 to 2025. This chart illustrates how Purple Biotech's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Purple Biotech for real-time trading data and today's change.
Purple Biotech Cash Flow Conversion Ratio Explained
Purple Biotech cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Purple Biotech Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Purple Biotech ranked by their cash flow conversion efficiency. Also see how much is Purple Biotech worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AEW UK REIT Plc
LSE:AEWU
|
0.047x |
|
ETHERNITY NETW.(DI) -001
F:82N
|
N/A |
|
Quinsam Capital Corporation
F:0Q4
|
-0.012x |
|
AIS Resources Ltd
V:AIS
|
-0.177x |
|
CirChem AB
ST:CIRCHE
|
-0.143x |
|
Collective Audience Inc.
NASDAQ:CAUD
|
0.868x |
|
Camerit AG
F:RTML
|
-0.041x |
|
East Coast Furnitech Public Company Limited
BK:ECF
|
-0.159x |
Annual Cash Flow Conversion Efficiency for Purple Biotech (2013–2025)
The table below shows the annual cash flow conversion efficiency of Purple Biotech from 2013 to 2025. Review PPBT FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.66 Million | $-5.54 Million | -0.573x | -31.31% |
| 2024-12-31 | $32.91 Million | $-14.37 Million | -0.437x | +24.86% |
| 2023-12-31 | $34.30 Million | $-19.93 Million | -0.581x | -63.50% |
| 2022-12-31 | $47.10 Million | $-16.73 Million | -0.355x | -51.69% |
| 2021-12-31 | $65.11 Million | $-15.25 Million | -0.234x | -54.50% |
| 2020-12-31 | $79.75 Million | $-12.09 Million | -0.152x | +70.49% |
| 2019-12-31 | $10.86 Million | $-5.58 Million | -0.514x | +33.32% |
| 2018-12-31 | $11.00 Million | $-8.48 Million | -0.771x | +23.24% |
| 2017-12-31 | $8.59 Million | $-8.63 Million | -1.004x | -114.60% |
| 2016-12-31 | $13.38 Million | $-6.26 Million | -0.468x | -33.35% |
| 2015-12-31 | $9.43 Million | $-3.31 Million | -0.351x | +94.01% |
| 2014-12-31 | $773.00K | $-4.53 Million | -5.855x | -1181.82% |
| 2013-12-31 | $-946.00K | $-512.00K | 0.541x | -- |
About Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, whi… Read more